For over 100 years, ergot alkaloids have been known to be powerful vasoconstrictor agents, even capable of causing gangrene (1). In the late 1940s, intravenous administration of ergotamine to patients with "organic heart disease" s found to cause electrocardiographic (ECG) changes and chest pain, believed to represent a direct vasoconstrictor effect of ergotamine on the coronary arteries, Stein and Weinstein (2) reported the responses of 30 patients. 15 of whom had a clinical diagnosis of coronary artery disease, to ergonovine, 0.5 to 0.6 mg in incremental doses . In 6 of these 15 patients, prior exercise testing had failed to produce ST segment depression. In all 15 . ergonovine administration resulted in ST segment depression or chest pain . or both . Chest pain was relieved by nitroglycerin . and repeat administration of ergonovine after nitroglycerin produced no or less prominent ECG changes in 10 patients . No chest pain or ECG changes were induced in 15 "controls ." Thus, ergonovine administration appeared to show promise as a diagnostic agent for coronary artery disease .
Ergonovine for provocalion of coronary spasm. in 1959 Prinzmetal described 32 patients, with angina primarily at rest, whose ECG showed striking ST segment elevation during episodes of pain (3) . He hypothesized that these findings represented severe, transient coronary artery vasoconstriction, superimposed on atherosclerotic plaque. "Prinzmetal's" or "variant-" angina gained credibility with the angfographic demonstration of spontaneous episodes of coronary artery spasm in patients with rest pain primarily associated with ST segment elevation (4-6) . However, such events were rarely seen during a rteriography . in part because of the common practice of premeditation with nitrates to avoid catheter-induced spasm of the coronary (especially right) artery . In 1975, Heupler et al . (7) ergonovine maleate to provoke coronary artery spasm during artcriucraphy in patients with known or suspected Prinzmetal' , angina . Shortly a fterward. i n two large series of patients who received ergonovine intravenously (8 .9) , the majority of patients with rest angina associated with ST segment changes (most commonly ST segment elevation) had coronary spasm of the "culprit vessel,' in association with ST segment changes similar to those noted during spontaneous attacks of angina and precipitation of the patient's characteristic chest pain . Conversely . ergonovine caused minimal, diffuse epicardial coronary oarrowing without ECG changes or chest pain in the majority of patients who had no ST segment changes during angina or who had an atypical chest pain syndrome . Even after reports of other pharmacologic agents or techniques (methacholine . cold pressor test, hyperventilation, epinephrine, histamine, exercise, for example), ergonovine has remained the reference standard for provocation of epicardial coronary artery spasm in patients with Prinzemetal's angina (10).
However, ergonovine has its down side . When it is administered intravenously. more than one third of patients experience nausea (and sometimes protracted retching) and headache, and a substantial minority become marke0y hypertensive. Further, if spasm is provoked. all the consequences of spontaneous spasm may be noted in the laboratory, including a marked decline in blood pressure and cardiac output, heart block . ventricular tachycardia and fibrillation and death (11) (12) (13) . The intracoronary administration of smaller doses of ergonovine (6 to 50 pg in cumlative doses) may avoid the untoward effects of this agent given intravenously. but experience with this approach is small (14).
The present study on intracoronary acetylcholine . In this issue of the Journal, Okumura and colleagues (15) report that intracoronary injection of acetylcholine in 70 patients with a clinical diagnosis of Prinzmetal's angina precipitated severe coronary constriction with chest pain or ECG changes (usually ST segment elevation), or both, in 63 . Conversely, acetylcholine produced lesser degrees of vasoconstriction without chest pain or ECG changes in all but I of 93 patients believed on clinical grounds not to have Prinzmetal's angina .
Thus, the sensitivity (90`'/0) and specificity (99 1 /") of acetylcholine for induction of coronary spasm in patients with Prinzmetal's angina rivals large published series of ergonovine testing 18,9,13). Further, the duration of acetylcholineinduced spasm was relatively brief even without nitroglycerin, reflecting the short half-life of acetylcholine and . with the exception of hradycardia (especially after acetylcholine administration in the right coronary artery). no complicalions were encountered . Thus, The investigators propose intracoronary acetylcholine as a safe and reliable provoca- Role of endothelium-derived relaxant factor. One would think that with the ubiquity of coronary artery disease in developed societies, Prinzmetal's angina due to coronary artery spasm would be rampant . Yet in the United States, it appears to be an uncommon ischemic syndrome . Clearly, we have much to learn regarding the mechanisms and clinical significance of coronary artery vasomotion .
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